Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon E Sprague

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
American Journal of Pharmaceutical Education|April 24, 2010
The fifteen year thank-youJon E Sprague
Drug Testing and Analysis|December 30, 2023
Influence of carbon side chain length on the in vivo pharmacokinetic and pharmacodynamic characteristics of illicitly manufactured fentanylsJeremy R Canfield, Jon E Sprague
Clinics in Laboratory Medicine|March 29, 2006
Hyperthermic syndromes induced by toxinsDaniel E Rusyniak, Jon E Sprague
Trends in Pharmacological Sciences|February 1, 2005
Neurotoxicity of MDMA (ecstasy): beyond metabolismJon E Sprague, David E Nichols
The Medical Clinics of North America|October 18, 2005
Toxin-induced hyperthermic syndromesDaniel E Rusyniak, Jon E Sprague
Pharmacology, Biochemistry, and Behavior|May 7, 2026
The abuse-related effects of illicitly manufactured fentanyls (IMFs): A mini reviewJeremy R Canfield, Jon E Sprague
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|July 28, 2025
Pediatric Overdose Deaths Increase as the Fourth Wave of the Opioid Epidemic Creates a Perfect StormJeremy R Canfield, Jon E Sprague
Archives of Toxicology|October 17, 2024
In vivo pharmacokinetic, pharmacodynamic and brain concentration comparison of fentanyl and para-fluorofentanyl in ratsJeremy R Canfield, Jon E Sprague
Basic & Clinical Pharmacology & Toxicology|August 24, 2016
The Pharmacology and Toxicology of the 'Holy Trinity'Joseph T Horsfall, Jon E Sprague
Chemical Research in Toxicology|March 9, 2016
Impact of Functional Group Modifications on Designer Phenethylamine Induced HyperthermiaGregory G Grecco, Jon E Sprague
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
American Journal of Pharmaceutical Education|April 24, 2010
The fifteen year thank-youJon E Sprague
Drug Testing and Analysis|December 30, 2023
Influence of carbon side chain length on the in vivo pharmacokinetic and pharmacodynamic characteristics of illicitly manufactured fentanylsJeremy R Canfield, Jon E Sprague
Clinics in Laboratory Medicine|March 29, 2006
Hyperthermic syndromes induced by toxinsDaniel E Rusyniak, Jon E Sprague
Trends in Pharmacological Sciences|February 1, 2005
Neurotoxicity of MDMA (ecstasy): beyond metabolismJon E Sprague, David E Nichols
The Medical Clinics of North America|October 18, 2005
Toxin-induced hyperthermic syndromesDaniel E Rusyniak, Jon E Sprague
Pharmacology, Biochemistry, and Behavior|May 7, 2026
The abuse-related effects of illicitly manufactured fentanyls (IMFs): A mini reviewJeremy R Canfield, Jon E Sprague
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|July 28, 2025
Pediatric Overdose Deaths Increase as the Fourth Wave of the Opioid Epidemic Creates a Perfect StormJeremy R Canfield, Jon E Sprague
Archives of Toxicology|October 17, 2024
In vivo pharmacokinetic, pharmacodynamic and brain concentration comparison of fentanyl and para-fluorofentanyl in ratsJeremy R Canfield, Jon E Sprague
Basic & Clinical Pharmacology & Toxicology|August 24, 2016
The Pharmacology and Toxicology of the 'Holy Trinity'Joseph T Horsfall, Jon E Sprague
Chemical Research in Toxicology|March 9, 2016
Impact of Functional Group Modifications on Designer Phenethylamine Induced HyperthermiaGregory G Grecco, Jon E Sprague
Pageof 10